Pr Philippe Moreau
- Spécialité
- Hématologue, expert myélome multiple
- Hôpital
- Centre Hospitalier Universitaire de Nantes
- Derniers articles
-
- Longitudinal assessments of MRD in high-risk newly diagnosed transplant-ineligible multiple myeloma in the BENEFIT study (IFM2020-05). (5 oct. 2026)
- Hospital at Home for BCMA-Directed Bispecific Antibodies in Multiple Myeloma: A Multicenter Real-World Feasibility and Safety Study. (1 oct. 2026)
- Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study. (30 août 2026)
- Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis. (24 août 2026)
- Blood-based MALDI-TOF mass spectrometry versus bone marrow MRD for monitoring multiple myeloma: CASSIOPEIA study results. (17 août 2026)